DiaMedica Therapeutics (DMAC) EBIT (2018 - 2026)

DiaMedica Therapeutics' EBIT history runs 9 years deep, the most recent figure standing at -$10.5 million for Q1 2026.

• On a quarterly basis, EBIT fell 28.71% year-over-year to -$10.5 million in Q1 2026; TTM through Mar 2026 was -$36.7 million, a 26.31% decrease from a year earlier, with the FY2025 full-year figure at -$34.4 million, down 28.92% from the prior year.
• EBIT retreated to -$10.5 million in Q1 2026 per DMAC's latest filing, from -$9.2 million in the prior quarter.
• Across five years, EBIT topped out at -$3.1 million in Q3 2022 and bottomed at -$10.5 million in Q1 2026.
• The 5-year median for EBIT is -$5.7 million (2024), against an average of -$6.3 million.
• Across the five-year window, EBIT increased 8.43% in 2022 and slumped 64.87% in 2023, its largest moves.
• Year by year, EBIT stood at -$4.0 million in 2022, then plunged by 47.19% to -$5.8 million in 2023, then plunged by 43.96% to -$8.4 million in 2024, then retreated by 9.43% to -$9.2 million in 2025, then declined by 13.77% to -$10.5 million in 2026.
• Per Business Quant, the three latest DMAC EBIT figures stand at -$10.5 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.0 million (Q3 2025).